Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).

Kane JM.

J Clin Psychiatry. 2006 May;67(5):831-2. No abstract available.

PMID:
16841634
3.

Atypical antipsychotics and cognition in schizophrenia.

Sharma T.

Arch Gen Psychiatry. 2002 Jun;59(6):571-2; author reply 573-5. No abstract available.

PMID:
12044209
4.

Clinical trials design lessons from the CATIE study.

Kraemer HC, Glick ID, Klein DF.

Am J Psychiatry. 2009 Nov;166(11):1222-8. doi: 10.1176/appi.ajp.2009.08121809. Epub 2009 Oct 1. Review.

PMID:
19797435
5.

Comparative effectiveness of antipsychotic drugs.

Messori A.

Am J Psychiatry. 2003 Mar;160(3):591-2; author reply 592-3. No abstract available.

PMID:
12611854
6.

Comparative effectiveness of antipsychotic drugs.

Adityanjee.

Am J Psychiatry. 2003 Mar;160(3):590-1; author reply 592-3. No abstract available.

PMID:
12611852
7.

The CATIE study and its implications for antipsychotic drug use.

Janicak PG.

Essent Psychopharmacol. 2006;7(1):53-63. No abstract available.

PMID:
16989293
8.

Heterogeneity of treatment effects in schizophrenia.

Stroup TS.

Am J Med. 2007 Apr;120(4 Suppl 1):S26-31. Review.

PMID:
17403379
9.

Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses.

Tandon R, Nasrallah HA.

Arch Gen Psychiatry. 2006 Aug;63(8):935-7; author reply 937-9. No abstract available.

PMID:
16894070
10.

CUtLASS confirms CATIE.

Mintz J, Kopelowicz A.

Arch Gen Psychiatry. 2007 Aug;64(8):978; author reply 979-80. No abstract available.

PMID:
17679644
11.
12.

Methodological issues in a comparative study of ziprasidone and risperidone.

Gharabawi GM, Bossie CA, Mahmoud R, Canuso CM, Lasser RA, Turkoz I, Greenspan A.

J Clin Psychiatry. 2006 Jan;67(1):162-3; author reply 163-4. No abstract available.

PMID:
16426103
13.

The CATIE study.

Teich J.

Am J Psychiatry. 2006 Mar;163(3):554-5; author reply 555-6. No abstract available.

PMID:
16513894
14.

Selecting antipsychotics in schizophrenia: lessons from CATIE.

Haddad P, Dursun SM.

J Psychopharmacol. 2006 May;20(3):332-4. No abstract available.

PMID:
16574710
16.

Clinical trial-based cost-effectiveness analyses of antipsychotic use.

Polsky D, Doshi JA, Bauer MS, Glick HA.

Am J Psychiatry. 2006 Dec;163(12):2047-56. Review.

PMID:
17151153
17.

Psychotic recurrence after antipsychotic discontinuation.

Zipursky RB.

Am J Psychiatry. 2002 Aug;159(8):1441-2; author reply 1442. No abstract available.

PMID:
12153856
18.

Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.

Keefe RS, Mohs RC, Bilder RM, Harvey PD, Green MF, Meltzer HY, Gold JM, Sano M.

Schizophr Bull. 2003;29(1):45-55.

PMID:
12908660
19.

Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE study.

Glazer WM, Conley RR, Citrome L.

CNS Spectr. 2006 Sep;11(9 Suppl 10):1-13; quiz 14.

PMID:
16946697
20.

Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

Rosenheck RA.

Arch Gen Psychiatry. 2006 Oct;63(10):1074-6. No abstract available.

PMID:
17015809
Items per page

Supplemental Content

Write to the Help Desk